Information on this Educational Activity
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other
individuals who are in a position to control the content of this activity to disclose any
relevant conflict of interest (COI) they may have as related to the content of this activity.
All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed
to providing its learners with high-quality CME/CE activities and related materials that
promote improvements or quality in healthcare and not a specific proprietary business interest
of a commercial interest.
The faculty reported the following financial relationships or
relationships to products or devices they or their spouse/life partner have with commercial
interests related to the content of this CME/CE activity:
Charles van der Horst, MD, has no significant financial relationships to disclose.
F. Parker Hudson, MD, has no significant financial relationships to disclose.
Editors in Chief
Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Merck, and ViiV and funds for research support from Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV. Dr. Kuritzkes disclosed in previous editions that he had received consulting fees from Bionor, Bristol-Myers Squibb, Celera, InnaVirVax, Janssen, Oncolys, Teva, Tobira, and ViroStatics and fees for non-CME/CE services from Merck and ViiV.
Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, TRIO Health, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV. Dr. Eron disclosed in previous editions that he had received consulting fees from AbbVie, Avexa, Bristol-Myers Squibb, Chimerix, EMD Serono, Inhibitex, Kainos, Koronis, Myriad, Pfizer, Roche Molecular Systems, Tobira, Tibotec/Janssen, and Virco; had received funds for research support from AbbVie, Bristol-Myers Squibb, Merck, Panacos, TaiMed, and Tobira; had served on speaker bureaus for Bristol-Myers Squibb, Gilead Sciences, Roche, Tibotec, and Virco; and had served on data and safety monitoring boards for TaiMed and Vertex.
Edward King, MA, has no real or apparent conflicts of interest to report.
Elaine P. Seeskin has no real or apparent conflicts of interest to report.
Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Additional Disclosure Information
The following faculty and staff have previously contributed to the content of this module and disclosed the following potential conflicts of interest:
Joel E. Gallant, MD, MPH, disclosed that he had received consulting fees from Abbott, Bristol-Myers Squibb, Gilead Sciences, Merck, Janssen, Japan Tobacco, Takara Bio, Theratechnologies, and ViiV/GlaxoSmithKline; had served on data and safety monitoring boards for Gilead Sciences, Koronis, and Sangamo; had received honoraria from Monogram Biosciences; had served on advisory boards for Pfizer, RAPID Pharmaceuticals, Tibotec, and ViiV; and had received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Roche, Sangamo, Vertex, and ViiV/GlaxoSmithKline at the time he contributed to this module.
Kathleen E. Squires, MD, disclosed that she had served on advisory boards for scientific purposes for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV; had served on advisory boards for marketing purposes for Gilead Sciences and Janssen; had served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Koronis, Pfizer, Schering-Plough, Tobira, and Tibotec; had received funds for research support from BioCryst, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Koronis, Merck, Schering-Plough, Tibotec, and Vertex; and had received consulting fees from GlaxoSmithKline and Merck at the time she contributed to this module.
Kimberly Y. Smith, MD, MPH, disclosed that she had served on advisory boards and as a consultant for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec, and ViiV and had participated in speaker bureaus for GlaxoSmithKline and Merck at the time she contributed to this module.
Satish Gopal, MD, MPH; Taryn O’Loughlin Gross, PhD; Michael Herce, MD; Arthur Jackson, MB BCh; Steven McGuire; and Heather Stieglitz, PhD; had no real or apparent conflicts of interest to report at the time that they contributed to this module.
The materials published on the Clinical Care Options Sites reflect the views of the
reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the
accredited provider, or the companies providing educational grants. The materials may discuss
uses and dosages for therapeutic products that have not been approved by the United States Food
and Drug Administration. A qualified healthcare professional should be consulted before using
any therapeutic product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
If you have technical queries about using this site, please contact: email@example.com.
If you have credit related queries or a complaint, please contact: firstname.lastname@example.org.
inPractice Hepatology current certification period
March 2, 2020
March 1, 2021
This program is intended for physicians and other healthcare professionals involved in the medical management of patients with or at risk of viral hepatitis.
The goal of this activity is to improve learners’ knowledge and competence regarding the clinical management of patients with viral hepatitis.
At the conclusion of this activity, participants should be able to:
- Appropriately diagnose and manage treatment-naive patients with viral hepatitis, including using correct pretreatment evaluations, selection of regimen according to viral and patient factors and guideline recommendations, on-treatment monitoring, and goals of therapy
- Optimally manage treatment-experienced patients with viral hepatitis, including selecting the appropriate regimen depending on treatment history and viral genotype, optimizing patient adherence, and minimizing adverse events
- Implement appropriate management strategies for special populations of patients with viral hepatitis, including those with acute infection, cirrhosis, or end-stage renal disease; children; pregnant women and those of childbearing age; men who have sex with men, incarcerated persons, HIV-coinfected patients; and those who are candidates for, or recipients of, transplantations
This program is supported by educational grants from AbbVie.
inPractice HIV current certification period
November 16, 2020
November 15, 2021
This activity is intended for physicians and other healthcare professionals involved in the management of patients with HIV.
The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of HIV disease.
At the conclusion of this activity, participants should be able to:
- Demonstrate an improvement in patient outcomes by applying information at the point of care
- Epidemiology and prevention: evaluate current demographic trends in HIV disease, modes of sexual and nonsexual transmission of HIV, and Centers for Disease Control and Prevention guidelines for implementing HIV testing, prevention, and infection control
- HIV-related basic science: Interpret the clinical significance of the HIV life cycle and natural history, virologic and immunologic aspects of disease pathogenesis, and factors associated with disease progression
- Clinical management: Integrate methods of HIV detection and diagnosis, patient history taking, syndromic evaluation for differential diagnosis, and health maintenance interventions into patient care; apply best practices in diverse aspects of patient care including issues in specific patient populations and coordination of care
- Disease manifestations: Manage the clinical presentation, diagnosis, treatment, and prophylaxis for the full range of opportunistic diseases, coinfections, and HIV-associated disorders that may occur in HIV-infected patients
- Initial antiretroviral therapy: Formulate state-of-the-art antiretroviral management strategies for treatment-naive patients, including attention to considerations when selecting regimens, monitoring and goals of therapy, and strategies for maximizing adherence
- Antiretroviral resistance: Appraise the clinical impact of antiretroviral resistance, including resistance assays and their interpretation, transmitted resistance, and patterns of emergent drug resistance associated with different regimens
- Treatment-experienced patients: Optimally manage treatment-experienced patients, including setting appropriate goals of therapy and selecting active agents when constructing new regimens
- Complications of antiretroviral therapy: Manage common antiretroviral toxicities and drug-drug interactions among antiretroviral agents and among antiretrovirals and concomitant agents
This program is supported by educational grants from Gilead Sciences, Inc., Merck Sharp & Dohme Corp. and ViiV Healthcare.
For inPractice Hepatology and HIV
Physician Continuing Medical Education (for Point of Care CME activities)
Instructions for Credit (Point of Care CME)
inPractice offers physicians
AMA PRA Category 1 CreditTM
for participation in this individual Internet point-of-care activity. Physicians may claim 0.5 credits per search. To claim point-of-care (PoC) CME credit through inPractice, eligible physicians must complete the following steps:
Register online at
- Execute a search or submit a clinical question
- Review the applicable clinical sources
- Click the "Claim CME Credit" button at the top right corner of the content you have viewed
- Complete the simple evaluation questions addressing clinical application of learnings from the sources you have consulted
After submitting the evaluation, you will be presented with your online CME certificate as a pdf file. Records of all CME activities completed can be found on the "My CME" page.